Skip to content
Peptide Atlas
All peptides

SS-31

Tier 1 · Human trials
Also known as Elamipretide · MTP-131 · Bendavia

The strongest evidence is Tier 1: human randomized controlled trials (TAZPOWER Phase 3 in Barth syndrome, MMPOWER-3 Phase 3 in primary mitochondrial myopathy, PROGRESS-HF Phase 2 in HFrEF, EVOLVE Phase IIa, RENEW Phase 3 in dry AMD) plus FDA accelerated approval as Forzinity (September 19, 2025) for Barth syndrome. Important nuance: the two pivotal Phase 3 trials in mitochondrial myopathy and heart failure FAILED their primary endpoints, with benefit only in post-hoc subgroups. The Barth syndrome approval rested on just 12 patients and a split 10:6 advisory panel vote. Cognitive, anti-aging, renal, ophthalmic and metabolic effects remain largely animal/in-vitro. Many consumer dosing/PK details derive from low-tier vendor sources.

Half-life
~3.5 h
Routes
Subcutaneous injection · Intravenous infusion
Goals
longevity · cognitive · body composition · healing
Cost / mg
Not recorded

How it works

SS-31 (elamipretide) is a small synthetic peptide that homes in on the powerhouses of the cell — the mitochondria. It carries a positive charge and rapidly penetrates cells, accumulating hundreds to thousands of times over inside the inner mitochondrial membrane. There it binds tightly to cardiolipin, a special fat found only in mitochondria that is essential for keeping the energy-producing machinery organized and working. By protecting cardiolipin, SS-31 helps preserve mitochondrial structure, keeps the electron transport chain assembled, boosts ATP (energy) production, and reduces harmful reactive oxygen species at their source rather than mopping them up after the fact. It has been studied in Barth syndrome, mitochondrial myopathy, heart failure, kidney injury, and age-related macular degeneration, and in September 2025 received FDA accelerated approval (as Forzinity) to improve muscle strength in Barth syndrome patients weighing at least 30 kg.

Overview

Overview

SS-31 — known clinically as elamipretide and also as MTP-131 and Bendavia — is a synthetic, mitochondria-targeted, cell-permeable aromatic-cationic tetrapeptide (sequence D-Arg-2',6'-dimethyltyrosine[Dmt]-Lys-Phe-NH2). It has a molecular formula of C32H49N9O5, a molecular weight of ~639.8-640.8 Da, and carries a net +3 charge at physiological pH (CAS# 736992-21-5).

It was discovered during opioid-receptor studies and developed in 2004 by Drs. Hazel Szeto and Peter Schiller (the "SS" reflects the Szeto-Schiller nomenclature), and has been studied since the early 21st century.

How it works

The peptide's alternating aromatic-cationic structure drives rapid cell penetration and accumulation at the inner mitochondrial membrane independent of membrane potential, with reported enrichment of more than 1,000-fold (up to 5,000-fold) above extracellular levels. Once there, SS-31 selectively binds cardiolipin — an anionic phospholipid found exclusively on the inner mitochondrial membrane (~20% of its lipid) that is essential for cristae formation, ETC supercomplex assembly, and ATP synthase function.

By binding cardiolipin at nanomolar affinity, SS-31:

  • preserves cristae curvature and stabilizes ETC supercomplexes (Complexes I, III, IV) and ATP synthase oligomers, improving coupling and raising ATP synthesis;
  • prevents cardiolipin peroxidation and cytochrome c peroxidase activity, limiting ROS production at the source;
  • prevents mitochondrial depolarization, inhibits mitochondrial permeability transition pore formation, and prevents Ca2+-induced swelling.

Note — contested mechanism: Sources disagree on whether SS-31 is best described as a mitochondria-targeted antioxidant that scavenges ROS, or as a structural agent that limits ROS production by stabilizing cardiolipin/ETC architecture. Both framings appear across the literature.

It is reported to have no effect on normal mitochondria.

Evidence and clinical development

SS-31/elamipretide has been evaluated across 7+ trials (including PROGRESS-HF, TAZPOWER, MMPOWER-3, ReCLAIM, EMBRACE, EVOLVE, and RENEW):

  • Barth syndrome (approved indication): The Phase 3 TAZPOWER trial (12 patients, 40 mg SC once daily, double-blind crossover) reported a mean +29.6 m improvement in 6-minute-walk distance over placebo during its 12-week placebo-controlled phase. The sustained 6MWT gains and improved LVEF/stroke volume reported at 168 weeks come from the open-label extension (TAZPOWER-OLE), which had no concurrent placebo comparator — so the long-term functional gains, unlike the +29.6 m figure, are not placebo-controlled. After a 2023 Complete Response Letter (citing small sample size) and a split 10:6 advisory-panel vote in October 2024, elamipretide received FDA accelerated approval on September 19, 2025 as Forzinity (NDA 215244) — the first disease-specific and first mitochondria-targeted drug approved — to improve muscle strength in adult and pediatric Barth syndrome patients weighing ≥30 kg.
  • Primary mitochondrial myopathy: The Phase 3 MMPOWER-3 trial (n=218, 40 mg/day SC, 24 weeks) did NOT meet its primary 6MWT endpoint (−3.2 m, p=0.69) nor fatigue score (p=0.37). Post-hoc, subjects with nuclear-DNA variants improved while mtDNA-variant subjects did not; the replisome cohort trended toward significance (p=0.06) and the CPEO subgroup improved significantly (p=0.0024).
  • Heart failure: In the Phase 2 PROGRESS-HF/EMBRACE trial (71 HFrEF patients, LVEF <40%), there was no significant change in LV end-systolic volume vs placebo, with strain signals in the high-dose cohort.
  • Dry AMD: The Phase 3 RENEW trial (~550 patients, ellipsoid-zone endpoint at 24 months) reached 50% enrollment by March 2025; development continues.
  • Renal: A single IV dose improved cortical perfusion after renal-artery stenting in the Phase IIa EVOLVE study.

Preclinical scope

Preclinical models show protective/restorative effects in heart failure, neurodegeneration, ischemia-reperfusion injury, metabolic syndromes, muscle atrophy/aging, atherosclerosis, osteoarthritis, diabetes, and glaucoma. Examples include restoration of state-3 respiration in aged mouse hearts within one hour, normalization of the ATP/ADP ratio (0.38→1.16) and Complex I/IV activity in a canine heart-failure model, 50-60% infarct-size reduction in rat/sheep ischemia-reperfusion, suppression of ferroptosis in diabetic cardiomyopathy and spinal-cord-injury models, and cognitive protection with enhanced BDNF signaling in LPS-treated and anesthesia-exposed mice.

Important: Cognitive, anti-aging, and most non-cardiac benefits remain animal/in-vitro only. Cognitive benefits have not been confirmed in humans, and there are zero clinical trials in cognitive impairment. The peptide is approved only for Barth syndrome — not for the other conditions studied.

Some consumer-facing sources market SS-31 directly and suggest pairing it with NAD+ precursors such as NMN for mitochondrial support; these are not established clinical recommendations.

What the research shows

93 findings extracted from the 18 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 13 human trial findings, 1 human study finding, 7 animal findings, 3 in vitro findings and 5 expert opinion findings.

  • human trialElamipretide was granted accelerated approval in the USA for use to improve muscle strength in adult and pediatric patients with Barth syndrome weighing ≥ 30 kg1

  • human trialElamipretide is under phase III clinical development for use in the treatment of dry age-related macular degeneration1

  • human trialElamipretide is under phase III clinical development for use in the treatment of mitochondrial myopathies1

  • human trialClinical trials PROGRESS-HF, TAZPOWER, MMPOWER-3, and ReCLAIM have been conducted with Elamipretide2

  • human trialMMPOWER-3 clinical trial did not demonstrate a significant benefit of elamipretide treatment in a genotypically diverse population of adults with primary mitochondrial myopathy (PMM)3

  • human trialSubjects with disease-causing nuclear DNA (nDNA) pathogenic variants receiving elamipretide experienced an improvement in the six-minute walk test (6MWT)3

  • human trialCohort of subjects with mitochondrial DNA (mtDNA) pathogenic variants showed no difference versus placebo3

  • human trialThe mtDNA replisome post-hoc cohort displayed an improvement on the 6MWT, trending towards significant, in the elamipretide group when compared with placebo3

Show 21 more findings

  • human trial6MWT results at week 24 in subjects with replisome variants showed a significant change in the elamipretide group subjects who had chronic progressive external ophthalmoplegia (CPEO)3

  • human trialElamipretide had a beneficial effect in PMM patients with mtDNA replisome disorders3

  • human trialElamipretide at 40 mg/day subcutaneously did not significantly improve 6-minute walk test distance compared to placebo at 24 weeks in primary mitochondrial myopathy patients4

  • human trialElamipretide at 40 mg/day did not significantly improve total fatigue score on the Primary Mitochondrial Myopathy Symptom Assessment compared to placebo at 24 weeks4

  • human trialElamipretide has shown promising improvements in cardiac hemodynamics at highest doses in early-phase clinical trials5

  • human studyClinical trials in heart failure and primary mitochondrial myopathy have failed13

  • animalPreclinical studies have demonstrated protective and restorative efficacy of Elamipretide in models of heart failure, neurodegeneration, ischemia-reperfusion injury, metabolic syndromes, and muscle atrophy and weakness2

  • animalElamipretide has been shown to increase left ventricular ejection fraction in dog models of heart failure with reduced ejection fraction5

  • animalElamipretide has been shown to prevent left ventricular remodeling in rats5

  • animalIn a rat MI model, liposomal composite hydrogel containing SS-31 improves cardiac function by scavenging excess ROS, improving mitochondrial dysfunction, and promoting angiogenesis11

  • animalTreatment with elamipretide significantly ameliorated LPS-induced learning and memory impairment during behavioral tests12

  • animalIn aged mice exposed to anesthesia, SS-31 treatment protected cognitive function13

  • animalUnapproved peptides like SS-31 demonstrate favorable tissue repair and metabolic outcomes in animal models15

  • in vitroSS-31@Fer-1 significantly improved H/R-induced cardiomyocyte viability and reduced LDH and CK-MB levels9

  • in vitroSS-31 treatment markedly inhibited mitochondrial dysfunction and cell injury in cultured podocytes stimulated with high glucose10

  • in vitroSS-31 treatment partly reversed the damage mediated by ALCAT1 overexpression in podocytes10

  • expert opinionThese effects have not been confirmed in humans13

  • expert opinionNo human clinical trials demonstrate prevention of dementia, prevention of decline, or improved cognitive function13

  • expert opinionNo human research suggests benefits to patients with dementia13

  • expert opinionSS-31 provides protection against ischaemia14

  • expert opinionSS-31 is in active clinical trials for various degenerative diseases14

How it works

Based on 8 animal findings, 11 in vitro findings, 11 expert opinion findings and 7 theoretical findings.

  • animalSS-31 acts as an inhibitor of mitochondrial oxidative damage11

  • animalSS-31 can target cytochrome c in the mitochondrial inner membrane of damaged cardiomyocytes11

  • animalSS-31 inhibits pathological ROS production, improving mitochondrial dysfunction11

  • animalMice treated with LPS exhibited mitochondrial dysfunction, oxidative stress, an inflammatory response, neural cell apoptosis, and loss of dendritic spines in the hippocampus12

  • animalElamipretide provided protective effects against mitochondrial dysfunction and oxidative stress12

  • animalElamipretide facilitated the regulation of brain-derived neurotrophic factor (BDNF) signaling, including the reversal of important synaptic-signaling proteins and increased synaptic structural complexity12

  • animalSS-31 improves cognitive functions in models of cognitive impairment by promoting mitochondrial and synaptic health and decreasing inflammation and pyroptosis13

  • animalSS-31 inhibits the opening of the mitochondrial permeability transition pore that forms under mitochondrial stress13

Show 29 more findings

  • in vitroSS-31 decreases mitochondrial reactive oxygen species production6

  • in vitroSS-31 prevents mitochondrial depolarization6

  • in vitroSS-31 prevents mitochondrial permeability transition pore formation6

  • in vitroSS-31 prevents Ca2+-induced mitochondrial swelling6

  • in vitroSS-31@Fer-1 reduced GSH and increased MDA levels, enhancing mitochondrial integrity and function compared to Fer-1 group9

  • in vitroSS-31@Fer-1 increased mitochondrial ROS and decreased MMP, indicating mitigation of H/R-induced cardiomyocyte cytotoxicity9

  • in vitroSS-31@Fer-1 maintained cellular iron homeostasis, as evidenced by increased expression of FTH, FTMT, FPN, and ABCB89

  • in vitroElevated levels of GPX4 and Nrf2 were observed in SS-31@Fer-1 group, while ACSL4 and PTGS2 levels were reduced9

  • in vitroSS-31@Fer-1 effectively suppressed ferroptosis in H/R-induced cardiomyocytes by maintaining cellular iron homeostasis, improving mitochondrial function, and inhibiting oxidative stress9

  • in vitroSS-31 is a cardiolipin antioxidant10

  • in vitroElamipretide (SS-31) is a novel mitochondrion-targeted antioxidant12

  • expert opinionElamipretide (Forzinity™) is a mitochondrial cardiolipin binder1

  • expert opinionElamipretide (SS-31) is a mitochondria-targeted tetrapeptide that selectively binds cardiolipin, a lipid found in the inner mitochondrial membrane2

  • expert opinionElamipretide stabilizes mitochondrial cristae structure, reduces oxidative stress, and enhances adenosine triphosphate (ATP) production2

  • expert opinionElamipretide has a unique structure allowing for uptake in a variety of cell types and highly selective mitochondrial targeting2

  • expert opinionSS-31 is a mitochondria-targeted drug that mitigates oxidative stress in dry AMD7

  • expert opinionSS-31 (Elamipretide) is a mitochondrial peptide that repairs cellular bioenergetics and reduces oxidative stress at the source14

  • expert opinionSS-31 easily crosses cell membranes and binds specifically to cardiolipin in the inner mitochondrial membrane, stabilising energy production14

  • expert opinionSS-31 repairs the internal structure of mitochondria, allowing them to produce clean, efficient energy again14

  • expert opinionSS-31 restores mitochondrial function (ATP)14

  • expert opinionSS-31 reduces neuroinflammation14

  • expert opinionSS-31/Elamipretide has known mechanisms of cytoprotection in AMD17

  • theoreticalElamipretide maintains cellular biogenetics and prevents reactive oxygen species-induced cell damage by targeting and stabilizing the cardiolipin-cytochrome c supercomplex5

  • theoreticalSS-31 is a mitochondria-targeting antioxidant6

  • theoreticalThe kidneys, specifically proximal tubules, have a high mitochondria density due to ATP requirements for solute reabsorption and fluid and electrolyte balance regulation6

  • theoreticalROS play a key role in various renal diseases including ischemia-reperfusion injury, drug-induced acute kidney injury, chronic kidney disease, diabetic nephropathy, and hypertensive kidney damage6

  • theoreticalSS-31 is an antioxidant that targets mitochondrial dysfunction as an emerging therapeutic strategy8

  • theoreticalSS-31 is a small peptide (D-Arg dimethyl-Tyr-Lys-Phe-NH2) that accumulates in mitochondria and scavenges reactive oxygen species13

  • theoreticalSS-31 binds to cardiolipin, a lipid exclusively expressed on the inner mitochondrial membrane13

How the body handles it

Based on 1 human trial finding and 2 animal findings.

  • human trialPharmacokinetic (exposure-response) analyses in the nDNA cohort showed a weak positive correlation between plasma elamipretide concentration and 6MWT improvement3

  • animalSS-31 is rapidly absorbed after subcutaneous administration and concentrates in the kidney, but is also taken up by the heart, liver, skeletal muscle, and lungs13

  • animalBrain concentrations are low compared to plasma, but it does cross the blood-brain barrier13

Safety and side effects

Based on 3 human trial findings, 2 human study findings, 1 in vitro finding and 5 expert opinion findings.

  • human trialElamipretide treatment was well-tolerated with most adverse events being mild to moderate in severity4

  • human trialSubcutaneous elamipretide is well-tolerated in patients with primary mitochondrial myopathy4

  • human trialIn early-phase clinical trials, elamipretide administration has not resulted in any severe adverse events5

  • human studySS-31 treatment leads to a few adverse events, though mostly mild13

  • human studyThe most common adverse event with SS-31 is injection site reaction13

  • in vitroSS-31 has no effects on normal mitochondria6

  • expert opinionTreatments longer than 4 weeks have not been studied, so long-term safety of SS-31 is not established in humans13

  • expert opinionIrritation at the injection site is a common adverse effect14

Show 3 more findings

  • expert opinionRigorous human safety data for unapproved peptides like SS-31 are scarce15

  • expert opinionThere is potential for serious harm to patients from unapproved peptides including SS-3115

  • expert opinionChallenges in retinal therapies include overcoming the blood-retinal barrier, surgical complications with implantable devices, and ensuring patient adherence16

What people use it for

Based on 1 human trial finding, 1 animal finding, 5 expert opinion findings and 1 theoretical finding.

  • human trialElamipretide became the first disease-specific treatment approved for Barth syndrome1

  • animalPreclinical studies suggest benefits in muscle aging, atherosclerosis, ischemia, osteoarthritis, diabetes, and glaucoma13

  • expert opinionSS-31 has been studied in heart failure and myopathies14

  • expert opinionSS-31 (elamipretide) is a prominent peptide marketed direct to patients15

  • expert opinionIntravitreal injections remain the standard for treating common retinal diseases including age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy16

  • expert opinionElamipretide is mentioned as an emerging therapy for retinal disease that has achieved FDA approval within the past five years or advanced to Phase 3 development16

  • expert opinionSS-31/Elamipretide is a potential candidate for AMD therapy17

  • theoreticalElamipretide may have therapeutic potential in preventing damage from oxidative stress and neuroinflammation that contribute to perioperative neurocognitive disorders (PND)12

Other findings

Based on 4 expert opinion findings and 1 theoretical finding.

  • expert opinionSS-31 was discovered while carrying out studies on opioid receptors6

  • expert opinionSS-31 has been extensively studied since the early twenty-first century6

  • expert opinionFrequent intravitreal administration creates significant treatment burden due to limited drug half-life and the chronic nature of these conditions16

  • expert opinionPromising innovations include sustained-release intravitreal implants, topical and subcutaneous delivery systems, and targeted methods like suprachoroidal and subretinal injections16

  • theoreticalSS-31 (also known as MTP-131, elamipretide, and Bendavia) is D-Arg-Dmt-Lys-Phe-NH26

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Contested

Whether SS-31 acts as a direct antioxidant that scavenges reactive oxygen species or works structurally to limit ROS production is described differently across sources

Several sources describe SS-31 as a mitochondria-targeted antioxidant that scavenges or decreases reactive oxygen species: "SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease" calls it "a mitochondria-targeting antioxidant," the Alzheimer's Drug Discovery Foundation report "SS-31 (also known as Elamipretide, Bendavia, and MTP-131)" states it "accumulates in mitochondria and scavenges reactive oxygen species," "Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice" terms it "a novel mitochondrion-targeted antioxidant," and "ALCAT1-mediated abnormal cardiolipin remodelling promotes mitochondrial injury in podocytes in diabetic kidney disease" calls it a "cardiolipin antioxidant." Other sources explicitly reject the free-radical-scavenger framing: "SS-31 (Elamipretide): Mechanism, Evidence, and Clinical Status" states the peptide "does not function as a conventional antioxidant that scavenges free radicals after they form. Instead, it limits ROS production at the source," and "SS-31 (Elamipretide) Dosing, Need to Know Information" describes it as reducing "oxidative stress at its source—inside the mitochondria where most ROS are produced—rather than just scavenging after the fact." Much of the divergence is terminological, since the sources using "antioxidant" also attribute the effect to cardiolipin binding and reduced ROS generation.

Limited evidence

The two pivotal Phase 3 trials failed their primary endpoints, with benefit only in post-hoc subgroups

MMPOWER-3 (n=218) did not meet its primary 6MWT endpoint (p=0.69); only post-hoc subgroups with nuclear-DNA/replisome/CPEO variants showed benefit, with the replisome cohort only trending toward significance (p=0.06). PROGRESS-HF (n=71) showed no significant change in LV end-systolic volume. One review states heart failure and mitochondrial myopathy trials 'have failed.' Barth syndrome approval rested on just 12 patients (TAZPOWER) and a split 10:6 advisory vote, following a 2023 Complete Response Letter for small sample size.

Contested

Approval status is stated inconsistently across sources

SS-31 (Elamipretide) Peptide Therapy — Mechanism, Evidence & Clinical Pearls for Medical Professionals - Dr. Raj Singh lists a PDUFA date of April 29, 2025 and describes the drug as pre-approval, while SS-31 (Elamipretide): Research Evidence & Safety Profile | PeptideInsight, SS-31 Elamipretide: Phase 2/3 Clinical Trial Data & Mechanism, SS-31 Peptide Dosing Guide: Elamipretide Protocol & Safety (2026), SS-31 (Elamipretide) Protocol — Complete Dosing &… | Peptide Initiative, and Elamipretide: First Approval. report FDA accelerated approval as Forzinity on September 19, 2025. This reflects different source dates rather than genuine disagreement, but readers should note the peptide was only approved for Barth syndrome, not the other conditions.

Contested

Reported plasma half-life values differ (2.5-3 h vs 3-4 h)

SS-31 Half Life — What Researchers Must Know reports a human plasma half-life of approximately 2.5-3 hours (IV), while SS-31 (Elamipretide): Research Evidence & Safety Profile | PeptideInsight, SS-31 (Elamipretide): Mechanism, Evidence, and Clinical Status | HealthRX.com, SS-31 (also known as Elamipretide®, Bendavia®, and ..., SS-31 (Elamipretide) Dosing, Need to Know Information,… | Peptide Initiative, SS-31 (Elamipretide) Protocol — Complete Dosing &… | Peptide Initiative, and SS-31 (Elamipretide) Dosing, Need to Know Information,… | Peptide Initiative report approximately 3-4 hours (subcutaneous or in dogs). The differences may reflect route of administration and species.

Limited evidence

Cognitive, anti-aging, and most non-cardiac benefits are animal/in-vitro only, not confirmed in humans

SS-31 (also known as Elamipretide®, Bendavia®, and ... states cognitive benefits have not been confirmed in humans and there are zero clinical trials for cognitive impairment; SS-31 Peptide (Elamipretide): The Ultimate Guide to Mitochondrial Health, Benefits, and Dosing — Peptide Resource describes many benefits with 'may' language from animal/experimental models. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. notes rigorous human safety data for the peptide as an unapproved product are scarce.

Other

Many dosing and pharmacokinetic claims come from low-tier commercial peptide-vendor sources

Detailed consumer dosing protocols (5-40 mg ranges, 4-6 week cycles, ~92% bioavailability, storage, NMN pairing) derive largely from tier 3-4 vendor/protocol sites (SS-31 Peptide Dosing Guide: Elamipretide Protocol & Safety (2026), SS-31 (Elamipretide) Dosing, Need to Know Information,… | Peptide Initiative, SS-31 (Elamipretide) Protocol — Complete Dosing &… | Peptide Initiative, SS-31 Peptide (Elamipretide): The Ultimate Guide to Mitochondrial Health, Benefits, and Dosing — Peptide Resource, SS-31 (Elamipretide) Dosing, Need to Know Information,… | Peptide Initiative) rather than peer-reviewed trials; some are explicitly anecdotal or theoretical.

Single source

Extended mitochondrial tissue residence (8-12 h) rests on a single source citing one 2015 rat study

The claim that mitochondrial tissue residence extends 8-12 hours despite short plasma half-life, and that peptide remained detectable in rat myocardial mitochondria 6-8 hours after plasma clearance, comes only from SS-31 Half Life — What Researchers Must Know (a vendor site referencing Dai et al. 2015).

Inconsistency

One review says elamipretide has not been studied beyond 4 weeks, yet much longer trials and years of cumulative exposure are documented elsewhere.

The Alzheimer's Drug Discovery Foundation Cognitive Vitality report on SS-31 states that "treatments longer than 4 weeks have not been studied, so long-term safety of SS-31 is not established in humans." This does not square with the rest of the record: the MMPOWER-3 randomized trial in primary mitochondrial myopathy dosed participants subcutaneously for 24 weeks, the TAZPOWER open-label extension in Barth syndrome reported sustained six-minute-walk gains out to 168 weeks, and a clinical summary states that no mitochondria-specific safety signal such as lactic acidosis has been observed across more than 2,000 patient-years of exposure. The 4-week statement reads as outdated or narrowly scoped rather than describing the full body of human data.

Inconsistency

EMBRACE and PROGRESS-HF are conflated as a single 71-patient HFrEF trial

EMBRACE (EMBRACE STEMI) was a reperfusion/infarct trial in first-time anterior STEMI patients, not a 71-patient HFrEF study. PROGRESS-HF was the ~71-patient HFrEF trial in patients with recent HF hospitalization and LVEF<40%. Merging them ('PROGRESS-HF/EMBRACE trial (71 HFrEF patients)') misattributes trial population and design.

What you may have heard

'Reported to have no effect on normal mitochondria' stated as established fact in both mechanism sections

This absolute claim rests on a single tier-2 source (SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney ..., a kidney-injury paper). An absence-of-effect claim on 'normal' mitochondria is difficult to prove and should be hedged; presenting it unqualified in the plain and technical mechanism overstates the evidence.

What you may have heard

'Reaches millimolar/high concentrations inside mitochondria within minutes' — millimolar is a very high specific claim

Millimolar intramitochondrial concentration is an extraordinary figure that would exceed most cardiolipin-binding stoichiometry expectations; it is sourced only to tier-3 expert-opinion sites (SS-31 (Elamipretide) Peptide Therapy — Mechanism, Evidence & Clinical Pearls for Medical Professionals - Dr. Raj Singh, SS-31 (Elamipretide): Mechanism, Evidence, and Clinical Status | HealthRX.com) and sits uneasily beside the more conservative '>1,000-fold enrichment' framing used elsewhere. Worth verifying against primary PK data.

Other

Once-daily dosing justified largely by 8-12 h mitochondrial residence, which the profile itself flags as a single vendor…

The rationale bridging a ~3.5 h plasma half-life to once-daily dosing leans on the extended tissue-residence claim, which is explicitly single-source and animal-only (SS-31 Half Life — What Researchers Must Know/Dai 2015). The approved once-daily regimen is regulatory fact, but the mechanistic justification should not be presented as if well-established.

What you may have heard

'first disease-specific and first mitochondria-targeted drug approved' phrasing

'First disease-specific drug approved' is vague/likely inaccurate as stated (many disease-specific drugs exist). The defensible claim is 'first drug approved for Barth syndrome' and 'first mitochondria-targeted therapeutic.' The current wording risks confusing readers.

Limited evidence

The muscle and walking benefits reported for elamipretide in Barth syndrome come from a single 12-patient trial and remain far from firmly established.

The frequently quoted 29.6-metre gain in six-minute-walk distance comes from TAZPOWER, which enrolled only 12 genetically confirmed Barth syndrome patients. The evidence was thin enough that the FDA first issued a Complete Response Letter in 2023 citing the small sample size, and an advisory committee split 10 votes to 6 on efficacy. When accelerated approval was finally granted in September 2025, it rested on an intermediate measure — improvement in knee-extensor muscle strength — rather than on the walking distance or long-term functional gains, and continued approval may depend on a confirmatory trial. The sustained improvements reported out to 168 weeks come from an open-label extension that had no placebo group for comparison.

Using it with other compounds

Check a stack
  • HexarelinComplementary

    Worth caution

    Both have cardioprotective, anti-apoptotic profiles against ischemia-reperfusion injury but by entirely different mechanisms: hexarelin via CD36/GH-independent inotropy and inflammasome suppression, SS-31 by stabilizing mitochondrial cardiolipin and reducing mitochondrial ROS. Convergence on cardiac protection makes them mechanistically complementary in research settings.

    Tier 4Theoretical — not established
  • GHK-CuSame downstream effect

    No documented conflict

    GHK-Cu reduces reactive oxygen species by activating SOD/SOD2 and delivers copper to cuproenzymes including cytochrome c oxidase, while lowering IL-6, TNF-α and IL-1β. SS-31 binds cardiolipin to stabilize ETC supercomplexes and cytochrome c, cutting mitochondrial ROS and modulating inflammation. Both converge on reduced oxidative stress and supported mitochondrial function through different molecular routes. Nothing in their described biology suggests a conflict between them.

    Tier 4Theoretical — not established

    Shares mitochondrial function · anti inflammatory

  • CerebrolysinComplementary

    May be complementary

    SS-31 protects mitochondrial energy production and reduces oxidative stress at the cardiolipin level, while Cerebrolysin improves neuronal energy metabolism and provides neurotrophic support. Pairing a targeted mitochondrial protector with a neurotrophic mixture addresses neuroprotection from two angles. Combination evidence is anecdotal.

    Tier 4Theoretical — not established

    Shares mitochondrial function · anti inflammatory · BDNF signaling

  • CortexinComplementary

    May be complementary

    SS-31 protects neurons at the mitochondrial level (cardiolipin/ETC stabilization, reduced mitochondrial ROS), while Cortexin provides receptor-level anti-excitotoxic, antioxidant and anti-apoptotic protection. Two different arms of neuroprotection (energy metabolism vs. glutamate/apoptosis) that plausibly complement one another.

    Tier 4Theoretical — not established

    Shares anti inflammatory · BDNF signaling

  • HumaninComplementary

    May be complementary

    Both aim to protect mitochondria and reduce oxidative/ischemic injury, but by different means: SS-31 physically stabilizes the inner-membrane cardiolipin and electron-transport supercomplexes to preserve ATP output and cut ROS, whereas humanin signals through receptors to trigger anti-apoptotic and anti-inflammatory programs. One protects mitochondrial machinery directly, the other signals survival — a genuinely complementary combination.

    Tier 4Theoretical — not established

    Shares mitochondrial function · anti inflammatory

  • KlothoComplementary

    May be complementary

    Both reduce oxidative stress and inflammation but at different points: SS-31 stabilizes the inner mitochondrial membrane (cardiolipin) to cut ROS production at the source, while Klotho boosts downstream Nrf2/FoxO antioxidant defenses and suppresses NLRP3/NF-κB inflammation. Together they address oxidative damage both where it is generated and how the cell defends against it.

    Tier 4Theoretical — not established

    Shares anti inflammatory

  • MOTS-cComplementary

    No documented conflict

    Both aim to protect and improve mitochondria but by different routes: MOTS-c works upstream through AMPK activation and Nrf2/ARE antioxidant gene expression, while SS-31 physically stabilizes cardiolipin and the electron-transport-chain supercomplexes to reduce ROS at the source. These are non-overlapping mechanisms converging on the same goal of better mitochondrial function and lower oxidative stress, making them a plausibly synergistic pairing.

    Tier 4Theoretical — not established

    Shares mitochondrial function · anti inflammatory

  • NoopeptComplementary

    No documented conflict

    SS-31 protects neurons by stabilizing mitochondria and cutting oxidative stress, while Noopept provides neurotrophic (BDNF) and anti-excitotoxic support. Both share mitochondrial, anti-inflammatory and BDNF-related tags but act through different targets, so they can converge on neuroprotection from complementary angles.

    Tier 4Theoretical — not established

    Shares mitochondrial function · anti inflammatory · BDNF signaling

  • SemaxComplementary

    No documented conflict

    SS-31 protects neurons by stabilizing mitochondria and reducing ROS, while Semax protects them through neurotrophin (BDNF/TrkB) signaling. The mitochondrial-protection plus neurotrophic-signaling combination targets different arms of neuroprotection, making them potentially complementary.

    Tier 4Theoretical — not established

    Shares anti inflammatory · BDNF signaling

  • EpithalonComplementary

    No documented conflict

    SS-31 stabilizes cardiolipin and cuts mitochondrial ROS at the source, whereas Epithalon's reported benefits run through telomerase and general antioxidant/senescence pathways. Both reduce oxidative/mitochondrial aging burden via unrelated mechanisms, making them plausibly complementary.

    Tier 4Theoretical — not established

    Shares mitochondrial function

Safety and side effects

Safety and Tolerability

Across clinical trials, elamipretide/SS-31 has generally been well-tolerated, with most adverse events mild to moderate.

Most common adverse events

  • Injection-site reactions (erythema, pruritus, irritation) — usually grade 1-2 and self-limiting
  • Headache
  • Fatigue

Notable safety observations

  • No severe adverse events reported in early-phase trials.
  • No mitochondria-specific safety signal (such as lactic acidosis) observed across more than 2,000 patient-years.

Limitations and cautions

  • Safety and effectiveness of Forzinity are not established for Barth syndrome patients weighing less than 30 kg.
  • For adults with severe renal impairment (eGFR <30 mL/min, not on dialysis), the FDA label recommends a reduced dose of 20 mg SC once daily.
  • Controlled trials have run up to 24 weeks (MMPOWER-3) and an open-label extension out to 168 weeks (TAZPOWER-OLE), and no mitochondria-specific safety signal has emerged across more than 2,000 patient-years of exposure. One earlier review stated that treatment beyond 4 weeks had not been studied; that no longer reflects the available data, though long-term safety in healthy individuals and for unapproved/compounded uses remains unestablished.
  • Rigorous human safety data for SS-31 as an unapproved/compounded product are scarce, with potential for serious harm; only the approved Forzinity product for Barth syndrome carries established regulatory safety data.

Reconstitution and handling

Formulation, Dosing & Storage

No dose has been established for this compound. No regulatory label exists for it, so the figures below are what sources report — not guidance.

These details combine the approved product label with lower-tier vendor/community sources. Consumer dosing protocols are not validated by peer-reviewed trials and should be treated cautiously.

Approved product (Forzinity)

  • Supplied as a ready-to-use solution containing 280 mg total per 3.5 mL vial (80 mg/mL) — no reconstitution required; the individual dose is 40 mg.
  • Per the FDA Forzinity label1, the dose is 40 mg subcutaneously once daily for patients ≥30 kg, taken at the same time each day regardless of food.
  • Severe renal impairment (eGFR <30 mL/min, not on dialysis): 20 mg SC once daily, per the FDA Forzinity label (1, tier 1).

Doses used in research

  • The 40 mg SC once-daily arm was used in MMPOWER-3 (24 weeks;4, tier 1) and TAZPOWER (12 weeks2).
  • An escalated 60 mg/day SC dose is being evaluated in open-label mitochondrial-myopathy cohorts.
  • Acute IV studies use 0.05 mg/kg/h (~4 mg/hour) infusion over 1-3 hours (renal-stent/STEMI pilots); IV doses ranging 0.01-0.25 mg/kg/h over 4 hours have also been tested.

Non-clinical / community dosing (anecdotal, unverified)

  • Low-tier vendor and community sources (tier 3-4) report ranges of 5-40 mg once daily (5-10 mg/day for "general support," 20-40 mg/day for intensive models), over 4-6 or 4-12 week cycles(vendor claim).
  • Some sources suggest pairing with NAD+ precursors such as NMN — this is not an established recommendation.

Reconstitution & storage (for lyophilized research material)

  • Reconstituted SS-31 should be used within 28 days when stored at 36-46°F (2-8°C).
  • Lyophilized powder remains stable up to 2 years frozen at −20°C or below.
  • Avoid freeze-thaw cycles.

Pharmacokinetics relevant to dosing

  • Subcutaneous bioavailability ~92%; peak plasma at 15-30 min (IV) or 30-60 min (SC).
  • Plasma half-life ~3-4 hours (some sources 2.5-3 h IV), but mitochondrial tissue residence may extend ~8-12 hours due to cardiolipin binding (single-source claim citing Dai et al. 2015 rat study).
  • Reaches high intramitochondrial concentrations within minutes; concentrates in kidney, with additional uptake by heart, liver, skeletal muscle, and lungs; crosses the blood-brain barrier (low brain vs plasma levels). Cleared by renal filtration and peptidase degradation of the C-terminal dimethyltyrosine residue.

Sources

Ordered by evidence quality — the strongest first.

  1. Elamipretide: First Approval.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  2. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  3. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  4. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  5. Targeting mitochondrial dysfunction with elamipretide.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  6. SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney ...(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  7. Innovative technologies for the treatment of dry age-related macular degeneration (AMD) - modern therapeutic perspectives and their future.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  8. Mitochondrial Dysfunction: The Silent Catalyst of Kidney Disease Progression.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  9. SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  10. ALCAT1-mediated abnormal cardiolipin remodelling promotes mitochondrial injury in podocytes in diabetic kidney disease.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  11. A ROS-Responsive Liposomal Composite Hydrogel Integrating Improved Mitochondrial Function and Pro-Angiogenesis for Efficient Treatment of Myocardial Infarction.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  12. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  13. SS-31 (also known as Elamipretide®, Bendavia®, and ...(opens in a new tab)
    Tier 3Web · alzdiscovery.org
  14. SS-31 (Elamipretide): Mechanism, Half-life & Research Data | Subject 157(opens in a new tab)
    Tier 3Web · subject157.com
  15. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  16. Beyond the injection: delivery systems reshaping retinal disease management.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  17. Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD).(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  18. Elamipretide: A Review of Its Structure, Mechanism of Action ...(opens in a new tab)
    Tier 4Web · pmc.ncbi.nlm.nih.gov

See something wrong or out of date on this page? Report it.